Cosmos Health Inc is a healthcare-focused company that specializes in providing innovative solutions and services across the pharmaceutical industry
The company primarily engages in the delivery of healthcare products, medical supplies, and related services, aiming to improve patient care and health outcomes. Cosmos Health is also involved in the development and distribution of generic and branded pharmaceuticals, emphasizing quality and accessibility. Through its various operations, the company seeks to create value for stakeholders while advancing healthcare delivery in diverse markets.
CHICAGO, IL / ACCESS Newswire / February 26, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQCOSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the addition of 60 new Stock Keeping Units (SKUs) to its Sky Premium Life nutraceutical brand.
Virax Biolabs supports HHS's focus on vaccine efficacy transparency, offering technology to assess immune responses and collaborate with developers to improve vaccine research.
CHICAGO, IL / ACCESS Newswire / February 18, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQCOSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
CHICAGO, IL / ACCESS Newswire / February 10, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQCOSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the filing of two new patent applications, covering groundbreaking developments in the treatment of glioma, an aggressive brain cancer, and hematologic malignancies, a complex group of blood cancers.
CHICAGO, IL / ACCESS Newswire / February 10, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQCOSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the appointment of Dimitris Moraitis as Vice President of Strategy & Operations.
CHICAGO, IL / ACCESS Newswire / February 7, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQCOSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its wholly owned subsidiary, Cana Laboratories ("Cana"), has entered into a new long-term ten-year contract manufacturing agreement with Provident Pharmaceuticals ("Provident"), a specialty pharmaceutical company, to produce four pharmaceutical products. These include Miorelique®, BE Union F.C., and two variations of Certorun, with a total production volume of 800,000 packs per year, or 8,000,000 packs over the ten-year period.
CHICAGO, IL / ACCESS Newswire / February 6, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQCOSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has received an initial purchase order of $578,460 from Al Rabwa International Services and Trading ("Al Rabwa") for its Sky Premium Life® food supplement products in Qatar.
CHICAGO, IL / ACCESS Newswire / February 5, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company")(NASDAQCOSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the filing of a patent application for multiple sclerosis (MS), a disabling autoimmune disorder affecting millions worldwide.
CHICAGO, IL / ACCESS Newswire / January 28, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQCOSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that, on January 27, 2025, its wholly owned subsidiary, CosmoFarm S.A. (the "Issuer" or "CosmoFarm"), entered into an agreement with a European bank to issue a €2,200,000 (approximately $2,293,830) secured bond (the "Loan").
CHICAGO, IL / ACCESS Newswire / January 27, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQCOSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the filing of a new patent application for allergic inflammation, a condition characterized by immune system hypersensitivity.
CHICAGO, IL / ACCESS Newswire / January 23, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQCOSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has entered into a supplemental exclusive distribution agreement with Virax Biolabs Group Limited NASDAQ:VRAXNASDAQVRAX)
CHICAGO, IL / ACCESS Newswire / January 22, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQCOSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has secured buy-out rights and exclusive licensing for two patented anticancer drugs targeting, among others, prostate, ovarian, and colorectal cancers.
CHICAGO, IL / ACCESS Newswire / January 21, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQCOSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its CEO, Greg Siokas, has increased his stake in the Company by acquiring a total of 647,809 common shares, valued at $425,000, across six transactions between December 20, 2024, and January 17, 2025.
CHICAGO, IL / ACCESSWIRE / January 13, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQCOSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has entered into a distribution agreement with Virax Biolabs Group Limited NASDAQ: VRAXNASDAQVRAX)
CHICAGO, IL / ACCESSWIRE / December 26, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQCOSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology at the Company's Research and Development division.
CHICAGO, IL / ACCESSWIRE / December 23, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQCOSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its CEO, Greg Siokas, and CFO, George Terzis, increased their stake in the Company by approximately 343,122 common shares, valued at $200,000, based on the closing share price on Friday, December 20, 2024.
CHICAGO, IL / ACCESSWIRE / November 26, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQCOSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that, on November 25, 2024, Taglich Brothers, Inc. ("Taglich") published an updated research report on the Company's common stock.
CHICAGO, IL / ACCESSWIRE / November 18, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQCOSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has adopted a strategy to include Bitcoin and Ethereum as part of its treasury reserve assets.
CHICAGO, IL / ACCESSWIRE / November 12, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQCOSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its Chief Executive Officer, Greg Siokas, has issued the following letter to the Company's shareholders.
CHICAGO, IL / ACCESSWIRE / November 1, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQCOSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its healthcare distribution business, operated through its wholly owned subsidiary, CosmoFarm S.A. ("CosmoFarm"), has achieved record sales.
How Cosmos Health’s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit
CHICAGO, IL / ACCESSWIRE / September 25, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQCOSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that sales of its proprietary brands, including Sky Premium Life, on Amazon in the United Kingdom have surged by 160%, increasing to $596,000 year-to-date in 2024 from $230,000 during the same period in 2023.
